<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27059986</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>01</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1433-0423</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>113</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft</Title>
          <ISOAbbreviation>Ophthalmologe</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Graves' ophthalmopathy].</ArticleTitle>
        <Pagination>
          <StartPage>349</StartPage>
          <EndPage>466</EndPage>
          <MedlinePgn>349-64; quiz 465-6</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00347-016-0239-3</ELocationID>
        <Abstract>
          <AbstractText>Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease and the full clinical picture can impair the quality of life of the patients considerably. Active inflammation can often be effectively treated by intravenous steroids/immunosuppression, however does not lead to full remission, since inflammation rather quickly results in irreversible fibrosis and increase of orbital fat. Very important is the control of risk factors (smoking cessation, good control of thyroid function, selenium supplementation) to prevent progression to severe stages. Treatment should rely on a thorough assessment of activity and severity of GO. Rehabilitative surgery (orbital decompression, squint surgery, eyelid surgery) is needed in many patients to restore function and appearance. Anti-thyroid-stimulating hormone (TSH) receptor antibodies do specifically occur in these patients and correlate to the course of thyroid and eye disease. The levels of these antibodies can be used for treatment decisions at certain time points of the disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Eckstein</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Zentrum für Augenheilkunde, Abteilung für Erkrankungen des vorderen Augenabschnittes, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland. anja.eckstein@uk-essen.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dekowski</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Zentrum für Augenheilkunde, Abteilung für Erkrankungen des vorderen Augenabschnittes, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Führer-Sakel</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Klinik für Endokrinologie und Stoffwechselerkrankungen, Universitätsklinikum Essen, Essen, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berchner-Pfannschmidt</LastName>
            <ForeName>U</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Labor für molekulare Augenheilkunde, Abteilung für Erkrankungen der vorderen Augenabschnitte, Universitätklinikum Essen, Essen, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Esser</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Zentrum für Augenheilkunde, Abteilung für Erkrankungen des vorderen Augenabschnittes, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>ger</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Endokrine Orbitopathie.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Ophthalmologe</MedlineTA>
        <NlmUniqueID>9206148</NlmUniqueID>
        <ISSNLinking>0941-293X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013956">Antithyroid Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013956" MajorTopicYN="N">Antithyroid Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019882" MajorTopicYN="N">Blepharoplasty</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019299" MajorTopicYN="N">Decompression, Surgical</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="N">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Graves’ disease</Keyword>
        <Keyword MajorTopicYN="N">Graves’ orbitopathy</Keyword>
        <Keyword MajorTopicYN="N">Immunmodulatory therapy</Keyword>
        <Keyword MajorTopicYN="N">Reconstructive surgical procedures</Keyword>
        <Keyword MajorTopicYN="N">Thyroid-stimulating hormone receptor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27059986</ArticleId>
        <ArticleId IdType="doi">10.1007/s00347-016-0239-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s00347-016-0239-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>J Endocrinol Invest. 2004 Mar;27(3):265-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15165003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2005 Feb;62(2):145-55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15670189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Ophthalmol. 1993 Nov 15;116(5):533-47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8238212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2009 Aug;94(8):2708-16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19491222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ophthalmologe. 2007 Sep;104(9):771-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17823804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eye (Lond). 2013 Mar;27(3):308-19</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23412559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thyroid. 1998 May;8(5):423-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9623735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ophthalmologe. 2013 Nov;110(11):1079-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24231915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2005 Oct;63(4):395-402</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16181231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Clin Invest. 1986 Oct;16(5):415-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3100309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Ophthalmol. 2009 Aug;93(8):1052-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19221109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2010 Feb 25;362(8):726-38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20181974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Endocrinol. 2008 Mar;158(3):273-85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18299459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horm Metab Res. 2015 Sep;47(10):797-803</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26287396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Endocrinol. 2006 Sep;155(3):387-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16914591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15998777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Med Klin (Munich). 2009 May 15;104(5):343-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19444414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exp Clin Endocrinol Diabetes. 1999;107 Suppl 5:S214-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10614926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2000 Apr 29;355(9214):1505-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10801172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2011 Feb;96(2):320-32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21239515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):339-58</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22632370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2012 Jan;97(1):E44-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22031515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thyroid. 2014 May;24(5):897-905</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24417307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):313-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22632368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orbit. 2010 Aug;29(4):177-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20812832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2015 Feb;100(2):422-31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25494967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2011 May 19;364(20):1920-31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21591944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2009 Oct;94(10):3700-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19723755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2007 Oct;67(4):607-12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17880407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2012 Dec;97(12):4454-63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23038682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2015 Feb;100(2):432-41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25343233</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
